TrialAnnals of the rheumatic diseases2018

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.

Dominique Baeten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.